Last reviewed · How we verify

NCT03328416

Augmented Reality Headset as Adjunct Display Monitor in AMIGO

Withdrawn NA Last updated 18 January 2020
What this trial tests

NA trial testing Augmented Reality in Malignancy. Withdrawn.

Timeline
1 January 2018
Primary endpoint
30 December 2019
30 December 2019

Quick facts

Lead sponsorBrigham and Women's Hospital
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Start date1 January 2018
Primary completion30 December 2019
Estimated completion30 December 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Brigham and Women's Hospital

Who can join

18 and older, any sex, with Malignancy or Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators' overarching goal is to investigate whether use of an augmented reality display system (utilized in addition to, not as a replacement to, conventional CT and MRI displays currently available in the procedure suite) streamlines the process of a procedure and/or provides ease of access to helpful pre-procedure and intra-procedure imaging information that would be more difficult and time-consuming to obtain with the conventional imaging display systems.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Augmented Reality

Trials testing the same drug.

Other recruiting trials for Malignancy

Currently open trials in the same condition.

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03328416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing